



AMR – a joint effort

Prof. Alfred Hera

HMA/EMA co-ordination meeting

Marienbad

May 2009

This presentation brings the
personal views of the author and
cannot be considered as
representing the official position of
the HMA






Excellent scientific guidance
on VMPs (EC/EMA/MSs)

Excellent scientific standard
for assessment of QSE of VMPs

High level of harmonisation of
rules for VMPs (incl.international
activities – VICH)

Industry delivering safe and
effective medicines, incl broad
spectrum antimicrobials bringing
new benefits – short / zero WP,
single dose

Growing knowledge in the
area of AMR (EMA,
EFSA, activities in the
human area



Reflection of the high level
scientific decisions on
prescription/use of drugs in
practice - not satisfactory

Pivotal differences between MS
in the veterinary / agricultural
structures and systems
(organisation, integration,
training, intensity of production)

Important differences in the
distribution systems for
VMPs, incl.financial bonuses

Current market model for
VMPs – relations - balance

Certain areas lacking the
legal support – e.g. data
collection

Lack of information leading
to improvement of
prescribing practices

..we see the gaping scissors...

Global & complex nature of AMR

Regulatory requirements for MA of ATM drugs

Postmarketing antimicrobial surveillance

Pharmacovigilance

Availability of up-to date product literature

Dispensing / distribution channels for ATMs

Restriction re advertisement

Use of ATM only where necessary (zootechnical measures first) + further restriction for specific molecules



Innovation

Availability of VMPs

Originators / generics

Competitiveness

Internal market

Availability of the old molecules

Animal health and welfare


Public health

Social / Economical issues (EU / MSs)

Needs AMR - fragile balance... **Requirements**

AMR is a real problem (CZ figures)

**Prevalence of Salmonella isolates in broiler chicken
National programme for eradication of salmonellosis
(NRL – SVÚ Praha)**




25 % of isolates of S. enteritidis

20% of isolates of other serotypes

AMR is a real problem (CZ figures)


Proportion of products of animal origin re. occurrence of *Salmonella* spp. strains resistant to nalidixic acid and ciprofloxacin (CZ)

NRL – SVÚ Praha




AMR is a real problem (CZ figures)

Comparison of AMR in isolates of *C. jejuni* isolated from broilers and from humans
NRL (SVÚ Olomouc)



AMR is a real problem (CZ figures)

Comparison of AMR in isolates of *C. jejuni* a *C. coli* from broilers (2008)
NRL (SVÚ Olomouc)



!! Need to involve human medicine

CZ example

- Antimicrobials worth of approx. 1 bilion CZK (approx. 30 mil. Euro) are prescribed unnecesarily
- Up-to $\frac{1}{2}$ of human ambulatory practices do not prescribe antimicrobials correctly
- 40 % of prescription of antimicrobials in human medicine is in paediatric practices

Avoidance of „simple“ solutions

- „..... prevention and control of resistance cannot be limited to restriction of use of certain active ingredients, which are seen as problematic at the first sight. We are facing a complex issue with intricated biological substance and this is the reason, why it is so difficult to find an effective solution“ (*Vlastimil Jindrák, CZ*)
- Evidence based decisions using the up-to-date science

What can we do

Get the data

- Consumption of veterinary antimicrobials
 - HMA strategic plan
 - Contact points + basic description of the state of art
 - First semester 2009 (CZ PRES)
 - EC/EMEA initiative
 - Technical discussions to follow
 - Autumn 2009
 - Co-ordinated action needed
 - MSs (HMA) / EC / EMEA / stakeholders
 - Detailed consideration deemed critical
 - Purpose, Format
 - Keeping the system simple as possible
 - Avoiding of frequent changes

Get the data



- **Information on resistance pattern in zoonotic agents**
 - EC / EFSA programmes
- **Information on resistance pattern in target animal pathogens**
 - At the level of the MSs
 - Publicly available
 - Treatment recommendations – e.g. CZ human activity
 - „Consensus on antibiotic usage“
 - „Antibiotic lists“



Influence of prescription behavior

- Availability of information on the prevalence of AMT at the level of the MSs
 - Zoonotic agents
 - Target animal pathogens
- Prescription audits

Let's

- Involve human medicines at the level of HMA
- Implement steps included in the Strategic plan
- Develop an action plan
- Initiate effective 3Cs
 - Co-ordination / Communication / Co-operation

Let's

- Start to speak the same language / To have the same understanding
 - Prudent use / responsible use
- Involve stakeholders
- Address the prescribers
- Start to deliver results
 - Data on sales of veterinary antimicrobial drugs
 - Harmonisation / update of the product literature

Let's

- Start to think about the legal changes
 - AFSA conference
 - TFWG on Veterinary Legislation
 - Availability of VMPs paper
 - Change to the existing legislation will be mandatory if we think about long term effects
 - Cascade
 - Records
 - Collection of data

Let's

- Take all components of this issue into the consideration
 - **Medicated feeds**
 - Current revision – do we go in the right direction ??

Let's

- Express the support to the current activities of the EMEA
 - Expertise
 - Provision of data
 - Follow-up of the scientific conclusions
- Avoid waisting of time and efforts
- Consider the time



Thank you for your attention !